Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Efect of 25 weeks probiotic supplementation on immune function of HIV patients
Gut Microbes, Volume 2, No. 2, Year 2011
Notification
URL copied to clipboard!
Description
Introduction: Studies with a follow-up of <8 weeks have indicated immune-preserving efects of yogurt probiotic supplementation among HIV patients. To evaluate the impact of 25 weeks use of probiotics, a randomized, double blind, controlled study was undertaken on 65 women who were naïve to anti-retroviral treatment. Results: Ten participants were excluded post-randomization due to non-eligibility. Thirty participants were assigned placebo, of whom 25 completed the study versus 19 of 25 completing the study in the probiotics group (p = 0.5). From baseline to 10 weeks follow-up, the CD4 count declined on average 3 CD4 cells/μl (95% Confdence Interval: -97; 91) with placebo versus an increase of 50 cells/μl (95% CI: -61; 162) with probiotics (p = 0.5). From baseline to 25 weeks, the CD4 count increased with 19 cells/μl (95% CI: -90; 129) in the placebo group versus 46 cells/μl (95% CI: -100; 192) with probiotics (p = 0.8). No diferences in immune markers, diarrhea incidence or adverse events were observed. Discussion: Lactobacillus GR-1 a nd RC-14 may be safely consumed at 2×109 CFU/day by moderately immune compromised HIV patients but this did not universally preserve immune-function. Patients and Methods: Women were randomized to receive oral capsules containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (2×109 colony forming units) or placebo twice daily for 25 weeks. The CD4 count and immune markers (IgG, IgE, IFNγ and IL-10) were measured at baseline and during follow-up, the occurrence of diarrhea was reported daily. © 2011 Landes Bioscience.
Authors & Co-Authors
Hummelen, Ruben B.
Canada, London
Lawson Health Research Institute
Netherlands, Rotterdam
Erasmus Mc
Changalucha, John M.
Netherlands, London
National Institute for Medical Research
Butamanya, Nicodemus L.
Tanzania
Sekou-toure Regional Hospital
Koyama, Tara E.
Canada, London
Lawson Health Research Institute
Habbema, J. Dik F.
Unknown Affiliation
Reid, Gregor
Netherlands, Rotterdam
Erasmus Mc
Statistics
Citations: 6
Authors: 6
Affiliations: 4
Identifiers
ISSN:
19490976
e-ISSN:
19490984
Research Areas
Disability
Health System And Policy
Infectious Diseases
Study Design
Randomised Control Trial
Cohort Study
Participants Gender
Female